-
01:41:49 PM

RHHBY Stock News

10/02/23 1:00 AM
OTC : RHHBY
conferences
Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD
Genentech, a member of the Roche Group, will present new data for Ocrevus ® and investigational Bruton’ s tyrosine kinase inhibitor fenebrutinib for multiple sclerosis, and Enspryng ® for neuromyelitis optica spectrum disorder. In total, Genentech will be presenting 36 abstracts at the 9th Joint ECTRIMS-ACTRIMS Meeting from October 11-13, 2023.
RHEA-AI
negative
09/07/23 7:00 AM
OTC : RHHBY
clinical trial
Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placebo Study met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six months Zilebesiran demonstrated
RHEA-AI
neutral
09/06/23 1:00 AM
OTC : RHHBY
clinical trial
FDA Accepts Application for Genentech’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition
Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has accepted the company’ s Biologics License Application for crovalimab, an investigational, novel anti-C5 recycling monoclonal antibody, for the treatment of paroxysmal nocturnal hemoglobinuria. The acceptance was based on results from the pivotal Phase III...
RHEA-AI
neutral
09/05/23 1:00 AM
OTC, NYSE : RHHBY, ROG, RHHBF
Economist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare
Roche– The Economist Impact report, Advancing the Frontier of Health and Technology Integration: The 2023 Digital Health Barometer, commissioned by Roche Diagnostics, examines the digital health environment in and across ten diverse countries from advanced economies to emerging markets: Australia, Brazil, France,...
RHEA-AI
positive
09/01/23 1:00 AM
OTC : RHHBY
clinical trial
Genentech’s Alecensa Delivers Unprecedented Phase III Results for People With ALK-Positive Early-Stage Lung Cancer
Genentech, a member of the Roche Group, announced today that the Phase III ALINA study evaluating Alecensa ®, compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival at a prespecified interim analysis. Alecensa demonstrated a statistically significant and clinically meaningful improvement in DFS as adjuvant...
RHEA-AI
neutral
08/29/23 5:00 AM
OTC : RHHBY
Roche’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenous Tecentriq , including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatment Administered under the skin within approx. seven minutes,
RHEA-AI
very positive
08/23/23 1:43 AM
OTC : RHHBY
clinical trial
Genentech Provides Update on Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
Genentech, a member of the Roche Group, has been made aware of an inadvertent disclosure of the second interim analysis of the Phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq ® versus Tecentriq alone as an initial treatment for people with PD-L1-high locally advanced or metastatic...
RHEA-AI
negative